Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019043020) ADENOVIRUS ARMED WITH BISPECIFIC T CELL ENGAGER (BITE)
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/043020 International Application No.: PCT/EP2018/073160
Publication Date: 07.03.2019 International Filing Date: 28.08.2018
IPC:
A61K 39/39 (2006.01) ,A61K 39/395 (2006.01) ,A61K 35/761 (2015.01) ,C07K 14/52 (2006.01) ,C07K 14/715 (2006.01) ,C07K 16/28 (2006.01) ,C07K 16/40 (2006.01) ,C12N 15/861 (2006.01) ,A61P 35/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
39
characterised by the immunostimulating additives, e.g. chemical adjuvants
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
[IPC code unknown for A61K 35/761]
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
52
Cytokines; Lymphokines; Interferons
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
705
Receptors; Cell surface antigens; Cell surface determinants
715
for cytokines; for lymphokines; for interferons
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
40
against enzymes
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
63
Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79
Vectors or expression systems specially adapted for eukaryotic hosts
85
for animal cells
86
Viral vectors
861
Adenoviral vectors
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants:
PSIOXUS THERAPEUTICS LIMITED [GB/GB]; PsiOxus House, 4-10 The Quadrant Barton Lane Abingdon Oxfordshire OX14 3YS, GB
Inventors:
CHAMPION, Brian; GB
BROMLEY, Alice, Claire, Noel; GB
Agent:
HAMBLETON, Bernadette, Angelina; Sterling IP LTD Orion House Bessemer Road Welwyn Garden City Hertfordshire AL7 1HH, GB
Priority Data:
1713765.428.08.2017GB
PCT/EP2017/07165529.08.2017EP
PCT/EP2017/07167429.08.2017EP
Title (EN) ADENOVIRUS ARMED WITH BISPECIFIC T CELL ENGAGER (BITE)
(FR) ADÉNOVIRUS ÉQUIPÉ D'UN ACTIVATEUR DE LYMPHOCYTES T BISPÉCIFIQUE (BITE)
Abstract:
(EN) An adenovirus comprising a sequence of formula (I) 5'ITR-B1-BA-B2-BX-BB-BY-B3-3'ITR wherein Βγ comprises a transgene cassette containing four transgenes, said genes encoding a FAP- BITE, CXLI O, CXL9, and IFN. The disclosure also extends to pharmaceutical composition comprising the virus, and use of the virus or formulation is treatment.
(FR) L'invention concerne un adénovirus comprenant une séquence répondant à la formule (I) 5'ITR-B1-BA-B2-BX-BB-BY-B3-3'ITR dans laquelle Βγ comprend une cassette de transgènes contenant quatre transgènes, lesdits gènes codant pour FAP-BITE, CXLI O, CXL9 et IFN. L'invention concerne également une composition pharmaceutique comprenant le virus, et l'utilisation du virus ou de la formulation comme traitement.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)